Clinical outcomes of pressure-enabled drug delivery for trans-arterial chemoembolization and radioembolization
Journal of Comparative Effectiveness Research · 2026-05 · 15 (5)
DOI: 10.57264/cer-2025-0144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-05. Verfasst von Deepshekhar Gupta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Analysis Group, Inc., Menlo Park, CA, 94025, USA. Hauptthemen laut MEDLINE: Radioembolization, Therapeutic, Liver Neoplasms, Chemoembolization, Therapeutic, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Prior research observed that pressure-enabled drug delivery (PEDD) counteracts intra-tumoral pressure during trans-arterial chemoembolization (TACE) and radioembolization (TARE), improving drug penetration, yet real-world evidence remains limited. This study examined outcomes associated with PEDD use, including in high-adopter facilities, and assessed potential cost avoidance associated with PEDD. Materials & methods: We used the Clarivate Real World Data repository to identify adults with hepatocellular carcinoma or secondary liver metastases who received TACE or TARE procedures (January 2020–March 2024). We compared baseline characteristics between PEDD and non-PEDD cohorts, then used a two-stage matching approach to develop a matched sample for comparative analyses. Facilities in the top fifth percentile of PEDD volume were examined separately.
Results
In total, 603 PEDD and 16,210 non-PEDD patients were identified. PEDD patients had higher baseline disease burden on average. In matched analyses, PEDD was associated with reduced rates of fatigue overall (20.9% vs 26.4%, p < 0.05) and 30-day inpatient visits among patients receiving TACE procedures (8.0% vs 20.5%, p < 0.05). In high-adopter facilities, PEDD use was associated with reduced lymphopenia among all patients (0.6% vs 5.2%, p < 0.05) and reduced fatigue (19.2% vs 39.7%, p < 0.05) and lymphopenia (0.0% vs 8.2%, p < 0.05) among patients with secondary liver metastases. PEDD use was linked to a per-patient charge avoidance of $7734 through fewer complications ($4599) and inpatient stays ($3135).
Conclusion
Despite greater patient comorbidity, PEDD use was associated with fewer post-procedure complications and lower healthcare resource utilization. Greater institutional experience may enhance patient outcomes. Reduced complications and hospitalizations can translate into cost avoidance, reinforcing the value of PEDD technology in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Analysis Group, Inc., Menlo Park, CA, 94025, USA.
- TriSalus Life Sciences, Inc., Westminster, CO, 80031, USA.
- Tulane University, School of Medicine, New Orleans, LA, 70112, USA.
Zitieren
APA
Gupta, D., Liu, Y., Miller-Rosales, C., Wei, F., Tuttle, E., Byers, E., Marshak, R., & Marshall, R. (2026). Clinical outcomes of pressure-enabled drug delivery for trans-arterial chemoembolization and radioembolization. Journal of Comparative Effectiveness Research, 15(5). https://doi.org/10.57264/cer-2025-0144
Vancouver
Gupta D, Liu Y, Miller-Rosales C, Wei F, Tuttle E, Byers E, et al. Clinical outcomes of pressure-enabled drug delivery for trans-arterial chemoembolization and radioembolization. Journal of Comparative Effectiveness Research. 2026;15(5). doi:10.57264/cer-2025-0144
BibTeX
@article{Gupta2026,
author = {Gupta, Deepshekhar and Liu, Yunjuan and Miller-Rosales, Chris and Wei, Fangzhou and Tuttle, Edward and Byers, Ekaterina and Marshak, Richard and Marshall, Richard},
title = {Clinical outcomes of pressure-enabled drug delivery for trans-arterial chemoembolization and radioembolization},
journal = {Journal of Comparative Effectiveness Research},
year = {2026},
volume = {15},
number = {5},
doi = {10.57264/cer-2025-0144}
}
EUVIMED